Associations among β-TrCP, an E3 ubiquitin ligase receptor, β-catenin, and NF-κB colorectal cancer

Journal of the National Cancer Institute

Volumn 96, Issue 15, 2004, Pages 1161-1170

  Ougolkov, Andrei ^a   Zhang, Bin ^a   Yamashita, Kaname ^a   Bilim, Vladimir ^b   Mai, Masayoshi ^a   Fuchs, Serge Y ^c   Minamoto, Toshinari ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b NIIGATA UNIVERSITY   (Japan)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; BETA TRANSDUCIN REPEAT CONTAINING PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; REGULATOR PROTEIN; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG; COMPLEMENTARY DNA; CTNNB1 PROTEIN, HUMAN; CYTOSKELETON PROTEIN; DNA; FBXW1B PROTEIN, HUMAN; RNA; TRANSACTIVATOR PROTEIN;

ADULT; AGED; APOPTOSIS; CANCER TISSUE; CELL NUCLEUS; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; COLORECTAL CANCER; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS; NICK END LABELING; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SIGNAL TRANSDUCTION; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; ADENOCARCINOMA; ARTICLE; CHEMISTRY; COLORECTAL TUMOR; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; SERODIAGNOSIS;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; APOPTOSIS; BETA CATENIN; BETA-TRANSDUCIN REPEAT-CONTAINING PROTEINS; COLORECTAL NEOPLASMS; CYTOSKELETAL PROTEINS; DNA, COMPLEMENTARY; DNA, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NF-KAPPA B; PRECIPITIN TESTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; TRANS-ACTIVATORS; UBIQUITIN-PROTEIN LIGASES;

EID: 3543078617     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/djh219     Document Type: Review

References (76)

1. Jemal A, Thomas A, Murray T, Than M. Cancer statistics, 2002. CA Cancer J Clin 2002;52:23-47.
2. Chung DC. The genetic basis of colorectal cancer: insights into critical pathways of tumorigenesis. Gastroenterology 2000;119:854-65.
3. Jass JR, Whitehall VL, Young J, Leggett BA. Emerging concepts in colorectal neoplasia. Gastroenterology 2002;123:862-76.
4. Minamoto T, Mai M, Ronai Z. K-ras mutation - early detection in molecular diagnosis and risk assessment of colorectal, pancreas and lung cancers. Cancer Detect Prev 2000;24:1-12.
5. Adjei AA. Blocking oncogenic ras signaling for cancer therapy. J Natl Cancer Inst 2001;93:1062-74.
6. Polakis P. The oncogenic activation of beta-catenin. Curr Opin Genet Dev 1999;9:15-21.
7. Taipale J, Beachy PA. The Hedgehog and Wnt signalling pathways in cancer. Nature 2001;411:349-54.
8. Wong NA, Pignatelli M. Beta-catenin - a linchpin in colorectal carcinogenesis. Am J Pathol 2002;160:389-401.
9. Minamoto T, Ougolkov A, Mai M. Detection of oncogenes in the diagnosis of cancers with active oncogenic signaling. Expert Rev Mol Diagn 2002; 2:565-75.
10. Kikuchi A. Tumor formation by genetic mutations in the components of the Wnt signaling pathway. Cancer Sci 2003;94:225-9.
11. Hugh TJ, Dillon SA, O'Dowd G, Getty B, Pignatelli M, Poston GJ, et al. Beta-catenin expression in primary and metastatic colorectal carcinoma. Int J Cancer 1999;82:504-11.
12. Brabletz T, Jung A, Reu S, Porzner M, Hlubek F, Kunz-Schughart LA, et al. Variable beta-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc Natl Acad Sci U S A 2001;98:10356-61.
13. Ougolkov AV, Yamashita K, Mai M, Minamoto T. Oncogenic beta-catenin and MMP-7 (matrilysin) cosegregate in late-stage clinical colon cancer. Gastroenterology 2002;122:60-71.
14. Zhang B, Ougolkov A, Yamashita K, Takahashi Y, Mai M, Minamoto T. Beta-catenin and ras oncogenes detect most human colorectal cancer. Clin Cancer Res 2003;9:3073-9.
15. Miyaki M, Iijima T, Kimura J, Yasuno M, Mori T, Hayashi Y, et al. Frequent mutation of beta-catenin and APC genes in primary colorectal tumors from patients with hereditary nonpolyposis colorectal cancer. Cancer Res 1999;59:4506-9.
16. Mirabelli-Primdahl L, Gryfe R, Kim H, Miller A, Luceri C, Dale D, et al. Beta-catenin mutations are specific for colorectal carcinomas with microsatellite instability but occur in endometrial carcinomas irrespective of mutator pathway. Cancer Res 1999;59:3346-51.
17. Aberle H, Bauer A, Stappert J, Kispert A, Kemler R. Beta-catenin is a target for the ubiquitin-proteasome pathway. EMBO J 1997;16:3797-804.
18. Hart M, Concordet JP, Lassot I, Albert I, del los Santos R, Durand H, et al. The F-box protein beta-TrCP associates with phosphorylated beta-catenin and regulates its activity in the cell. Curr Biol 1999;9:207-10.
19. Winston JT, Strack P, Beer-Romero P, Chu CY, Elledge SJ, Harper JW. The SCFbeta-TRCP-ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in IkappaBalpha and beta-catenin and stimulates IkappaBalpha ubiquitination in vitro. Genes Dev 1999;13:270-83.
20. Liu C, Kato Y, Zhang Z, Do VM, Yankner BA, He X. Beta-Trcp couples beta-catenin phosphorylation-degradation and regulates Xenopus axis formation. Proc Natl Acad Sci U S A 1999;96:6273-8.
21. Fuchs SY, Spiegelman VS, Suresh Kumar KG. The many faces of beta-TrCP E3 ubiquitin ligase receptors: reflections in the magic mirror of cancer. Oncogene 2004;23:2028-36.
22. Maniatis T. A ubiquitin ligase complex essential for the NF-kappaB, Wnt/Wingless, and Hedgehog signaling pathways. Genes Dev 1999;13: 505-10.
23. Peters JM. Emi1 proteolysis: how SCFbeta-Trcp1 helps to activate the anaphase-promoting complex. Mol Cell 2003;11:1420-1.
24. Chiaur DS, Murthy S, Cenciarelli C, Parks W, Loda M, Inghirami G, et al. Five human genes encoding F-box proteins: chromosome mapping and analysis in human tumors. Cytogenet Cell Genet 2000;88:255-8.
25. Spiegelman VS, Slaga TJ, Pagano M, Minamoto T, Ronai Z, Fuchs SY. Wnt/beta-catenin signaling induces the expression and activity of betaTrCP ubiquitin ligase receptor. Mol Cell 2000;5:877-82.
26. Japanese Society for Cancer of the Colon and Rectum. Japanese classification of colorectal carcinoma. First English ed. Tokyo (Japan): Kanehara & Co.; 1997. p. 27-66.
27. TNM classification of malignant tumours. In: Sobin LK, Wittekind C, editors. UICC International Union Against Cancer. 5th ed. New York (NY): John Wiley & Sons; 1997. p. 66-9.
28. Gayet J, Zhou XP, Duval A, Rolland S, Hoang JM, Cottu P, et al. Extensive characterization of genetic alterations in a series of human colorectal cancer cell lines. Oncogene 2001;20:5025-32.
29. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-9.
30. Puissant C, Houdebine LM. An improvement of the single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Biotechniques 1990;8:148-9.
31. Spiegelman VS, Stavropoulos P, Latres E, Pagano M, Ronai Z, Slaga TJ, et al. Induction of beta-transducin repeat-containing protein by JNK signaling and its role in the activation of NF-kappaB. J Biol Chem 2001;276: 27152-8.
32. Spiegelman VS, Tang W, Katoh M, Slaga TJ, Fuchs SY. Inhibition of HOS expression and activities by Wnt pathway. Oncogene 2002;21:856-60.
33. Harlow E, Lane D. Using antibodies: a laboratory manual. Plainview (NY): Cold Spring Harbor Laboratory Press; 1999.
34. Tornusciolo DR, Schmidt RE, Roth KA. Simultaneous detection of TDT-mediated dUTP-biotin nick end-labeling (TUNEL)-positive cells and multiple immunohistochemical markers in single tissue sections. Biotechniques 1995;19:800-5.
35. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995;267:1456-62.
36. Lassot I, Segeral E, Berlioz-Torrent C, Durand H, Groussin L, Hai T, et al. ATF4 deregulation relies on a phosphorylation-dependent interaction with the SCFbetaTrCP ubiquitin ligase. Mol Cell Biol 2001;21:2192-202.
37. Davis M, Hatzubai A, Andersen JS, Ben-Shushan E, Fisher GZ, Yaron A, et al. Pseudosubstrate regulation of the SCFbeta-TrCP ubiquitin ligase by hnRNP-U. Genes Dev 2002;16:439-51.
38. Karin M, Cao Y, Greten FR, Li ZW. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002;2:301-10.
39. Verma IM, Stevenson J. IkappaB kinase: beginning, not the end. Proc Natl Acad Sci U S A 1997;94:11758-60.
40. Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem 1998;67:425-79.
41. Hershko A, Ciechanover A, Varshavsky A. The ubiquitin system. Nat Med 2000;6:1073-81.
42. Ciechanover A, Orian A, Schwartz AL. Ubiquitin-mediated proteolysis: biological regulation via destruction. Bioessays 2000;22:442-51.
43. Ciechanover A, Schwartz AL. Ubiquitin-mediated degradation of cellular proteins in health and disease. Hepatology 2002;35:3-6.
44. Fuchs SY. The role of ubiquitin-proteasome pathway in oncogenic signaling. Cancer Biol Ther 2002;1:337-41.
45. Shimura H, Hattori N, Kubo S, Mizuno Y, Asakawa S, Minoshima S, et al. Familial Parkinson disease gene product, perkin, is a ubiquitin-protein ligase. Nat Genet 2000;25:302-5.
46. Jiang YH, Armstrong D, Albrecht U, Atkins CM, Noebels JL, Eichele G, et al. Mutation of the Angelman ubiquitin ligase in mice causes increased cytoplasmic p53 and deficits of contextual learning and long-term potentiation. Neuron 1998;21:799-811.
47. Daujat S, Neel H, Piette J. MDM2: life without p53. Trends Genet 2001; 17:459-64.
48. Alarcon-Vargas D, Ronai Z. p53-MDM2-the affair that never ends. Carcinogenesis 2002;23:541-7.
49. Reynisdottir I, Polyak K, Iavarone A, Massague J. Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta. Genes Dev 1995;9:1831-45.
50. Porter PL, Malone KE, Heagerty PJ, Alexander GM, Gatti LA, Firpo EJ, et al. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 1997;3:222-5.
51. Catzavelos C, Bhattacharya N, Ung YC, Wilson JA, Roncari L, Sandhu C, et al. Decreased levels of the cell-cycle inhibitor 27Kip1 protein: prognostic implications in primary breast cancer. Nat Med 1997;3:227-30.
52. Mori M, Mimori K, Shiraishi T, Tanaka S, Ueno H, Sugimachi K, et al. p27 expression and gastric carcinoma. Nat Med 1997;3:593.
53. Guo Y, Sklar GN, Borkowski A, Kyprianou N. Loss of the cyclin-dependent kinase inhibitor p27Kip1 protein in human prostate cancer correlates with tumor grade. Clin Cancer Res 1997;3:2269-74.
54. Masciullo V, Sgambato A, Pacilio C, Pucci B, Ferrandina G, Palazzo J, et al. Frequent loss of expression of the cyclin-dependent kinase inhibitor p27 in epithelial ovarian cancer. Cancer Res 1999;59:3790-4.
55. Bamberger AM, Riethdorf L, Milde-Langosch K, Bamberger CM, Thuneke I, Erdmann I, et al. Strongly reduced expression of the cell cycle inhibitor p27 in endometrial neoplasia. Virchows Arch 1999;434:423-8.
56. Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 1997;3: 231-4.
57. Hirano K, Minamoto T. Altered expression of p53 and p27 proteins, alone or combined, as a predictor of metastatic potential in early invasive carcinomas of colon and rectum - a comparative clinicopathologic and molecular analysis. Cancer Detect Prev 2000;24:343-55.
58. Carrano AC, Eytan E, Hershko A, Pagano M. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol 1999;1:193-9.
59. Sutterluty H, Chatelain E, Marti A, Wirbelauer C, Senften M, Muller U, et al. p45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells. Nat Cell Biol 1999;1:207-14.
60. Tsvetkov LM, Yeh KH, Lee SJ, Sun H, Zhang H. p27Kip1 ubiquitination and degradation is regulated by the SCFSkp2 complex through phosphorylated Thr187 in p27. Curr Biol 1999;9:661-4.
61. Hershko D, Bornstein G, Ben-Izhak O, Carrano A, Pagano M, Krausz MM, et al. Inverse relation between levels of p27Kip1 and of its ubiquitin ligase subunit Skp2 in colorectal carcinomas. Cancer 2001; 91:1745-51.
62. Shim EH, Johnson L, Noh HL, Kim YJ, Sun H, Zeiss C, et al. Expression of the F-box protein SKP2 induces hyperplasia, dysplasia and low-grade carcinoma in the mouse prostate. Cancer Res 2003;63:1583-8.
63. Shigemasa K, Gu L, O'Brien TJ, Ohama K. Skp2 overexpression is a prognostic factor in patients with ovarian adenocarcinoma. Clin Cancer Res 2003;9:1756-63.
64. Kroll M, Margottin F, Kohl A, Renard P, Durand H, Concordet JP, et al. Inducible degradation of IkappaBalpha by the proteasome requires interaction with the F-box protein h-betaTrCP. J Biol Chem 1999;274: 7941-5.
65. Nakayama K, Hatakeyama S, Maruyama S, Kikuchi A, Onoe K, Good RA, et al. Impaired degradation of inhibitory subunit of NF-kappaB (IkappaB) and beta-catenin as a result of targeted disruption of the beta-TrCP1 gene. Proc Natl Acad Sci U S A 2003;100:8752-7.
66. Yaron A, Gonen H, Alkalay I, Hatzubai A, Jung S, Beyth S, et al. Inhibition of NF-kappaB cellular function via specific targeting of the IkappaB-ubiquitin ligase. EMBO J 1997;16:6486-94.
67. Schmid RM, Adler G. NF-kappaB/Rel/IkappaB: implications in gastrointestinal diseases. Gastroenterology 2000;118:1208-28.
68. Karin M, Lin A. NF-kappaB at the crossroads of life and death. Nat Immunol 2002;3:221-7.
69. Pahl HL. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 1999;18:6853-66.
70. Fong A, Sun SC. Genetic evidence for the essential role of beta-transducin repeat-containing protein in the inducible processing of NF-kappaB2/p100. J Biol Chem 2002;277:22111-4.
71. Lang V, Janzen J, Fischer GZ, Soneji Y, Beinke S, Salmeron A, et al. betaTrCP-mediated proteolysis of NF-kappaB1 p105 requires phosphorylation of p105 serines 927 and 932. Mol Cell Biol 2003;23:402-13.
72. Saitoh T, Katoh M. Expression profiles of beta TRCP1 and beta TRCP2, and mutation analysis of betaTRCP2 in gastric cancer. Int J Oncol 2001;18: 959-64.
73. Gerstein AV, Almeida TA, Zhao G, Chess E, Shih IeM, Buhler K, et al. APC/CTNNB1 beta-catenin) pathway alterations in human prostate cancers. Genes Chromosomes Cancer 2002;34:9-16.
74. Reifenberger J, Knobbe CB, Wolter M, Blaschke B, Schulte KW, Pietsch T, et al. Molecular genetic analysis of malignant melanomas for aberrations of the Wnt signaling pathway genes CTNNB1, APC, ICAT and BTRC. Int J Cancer 2002;100:549-56.
75. Soldatenkov VA, Dritschilo A, Ronai Z, Fuchs SY. Inhibition of homologue of Slimb (HOS) function sensitizes human melanoma cells for apoptosis. Cancer Res 1999;59:5085-8.
76. Zhang YW, Nakayama K, Nakayama KI, Morita I. A novel route for connexin 43 to inhibit cell proliferation: negative regulation of S-phase kinase-associated protein (Skp2). Cancer Res 2003;63:1623-30.